Liability Related to Sale of Future Royalties (Tables)

3 Months Ended

Mar. 31, 2025

The following table sets forth information on our liability related to sale of future royalties (in thousands):

Liability related to sale of future royalties, net as of December 31, 2024	$	542,212
Royalty payments to Royalty Pharma		(12,891	)
Interest expense related to sale of future royalties		18,670
Amortization of issuance costs related to sale of future royalties		152
Liability related to sale of future royalties, net as of March 31, 2025	$	548,143
Less: Current portion (1)		(12,002	)
Liability related to sale of future royalties, net as of March 31, 2025 – Non-current	$	536,141

(1)	Included in other current liabilities in our condensed consolidated balance sheet.